Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Unknown × Cardiotoxicity × Clear all

Phase

Phase NA 14 Phase 3 3 Phase 4 2 Phase 2 2 Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 26 Carcinoma, Hepatocellular 24 Colorectal Neoplasms 18 Carcinoma, Non-Small-Cell Lung 17 Neoplasms 16 Stomach Neoplasms 15 Leukemia, Myeloid, Acute 14 Colonic Neoplasms 11 Rectal Neoplasms 10 Prostatic Neoplasms 10 Lung Neoplasms 10 Precursor Cell Lymphoblastic Leukemia-Lymphoma 9 Neoplasm Metastasis 7 Leukemia 7 Pancreatic Neoplasms 6 NSCLC 5 Multiple Myeloma 5 Esophageal Neoplasms 5 Recurrence 4 Nasopharyngeal Carcinoma 4 Head and Neck Neoplasms 4 Glioblastoma 4 Gestational Trophoblastic Disease 4 Esophageal Squamous Cell Carcinoma 4 Cholangiocarcinoma 4 Uterine Cervical Neoplasms 3 Stomatitis 3 Small Cell Lung Carcinoma 3 Polycystic Ovary Syndrome 3 Pain, Postoperative 3

Interventions

Trimetazidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04939857 2021-06-25

Effect of Trimetazidine on Radiotherapy-induced Heart Damage.

Peking University Third Hospital

Phase 2/3 Unknown

Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon ⚡